AACR Annual Meeting 2019 - InSphero

AACR Annual Meeting 2019

Mar 29 - Apr 03, 2019

Enabling Innovative Cancer Research

jump to section

Meet InSphero Oncology Experts at AACR 2019 to learn how you can gain greater translational insights using our 3D™ InSight Oncology platform with assay ready tumor models and services.

  • Receive highly predictive 3D models that mimic complex in vitro tumor microenvironment, delivered assay-ready to your lab
  • Discover more with tailored oncology services for drug efficacy testing and immuno-oncology
  • Rely on ISO 9001:2015 quality-controlled microtissues
  • Reduce animal testing with a pharma-validated 3D liver model

Schedule a Meeting

assay-ready spheroid tumor models for cancer research

We combine tumor, stromal, and immune components to produce custom-designed 3D in vitro models that better reflect human cancer biology

Search for Cures with Tailored Oncology Services

Talk to our team at AACR to learn how we can work for you. 3D InSight™ Oncology Services combine the predictive power of our physiologically relevant cell-line and PDX tumor models with the 3D applications expertise of our scientific staff.

  • Custom Tumor Model Development from cancer cell lines or PDX material
  • Drug efficacy testing
  • Combinatorial Drug Testing
  • Tumor Relapse Assay
  • Antibody Penetration
  • Immuno-oncology services, such as CAR-T Cell Efficacy Testing and Immuno-modulatory Antibody Efficacy Testing

Conference Detail

AACR 2019 Annual Meeting
March 29 – April 3, 2019
Georgia World Congress Center
Atlanta, GA USA

Program Information
View the AACR 2019 Online Itinerary Planner
Download AACR 2019 Event App

  • InSphero Booth: 3963

jump to section
jump to section

Poster Presentation

Session PO.TB01.01 - 3D Models

Sunday, March 31, 1 – 5 PM, Poster Section 2, Number 52/24
PDX-derived 3D InSight™ tumor microtissues as ex vivo human experimental models for evaluating therapeutic responses
The selection of appropriate preclinical models comes always with the major question on how accurately and robustly they can represent the complexity of human disease. Patient-derived xenograft (PDX) models faithfully preserve the biological features and the genetic expression profile of human tumor specimens. However, one limiting aspect of patient-derived models is the replacement of the human host microenvironment by murine stroma within the tumor. Lack of cross-species compatibility compromises the induction of a broad range of signaling pathways that cannot be entirely recapitulated. With our 3D in vitro 3D InSight™ PDX Microtissues, we provide a relevant physiological environment and a strategy to assess candidate drugs for novel therapeutic approaches.

Session PO.TB01.01 - 3D Models

Sunday, March 31, 1 – 5 PM, Poster Section 2, Number 57/29
Development of an in vitro 3D model system for testing PD-1/ PDL-1 immune checkpoint inhibitors
Background immune checkpoint inhibitors provide a new hope for cancer patients not responding to chemotherapy by removing the tumor protection against immune cell attacks. Nevertheless, only a subset of patients responds well to these therapies, and recent studies demonstrated that the mechanisms of action are more complex than expected, often involving multiple cell types of the immune system. Importantly, for a better understanding and assessment of immune cell eliciting cell tumor death, there is a need to have fully human, complex 3D in vitro models. We developed a 3D tumor-immune cell co-culture model and show here acquired insights on the modulatory capacity of immune checkpoint inhibitors. We have developed a 3D tumor-immune cell co-culture model and evaluated its application to study the effect of immune checkpoint inhibitors on tumor viability, cytokine secretion, and immune cell infiltration. Our novel in vitro immuno-oncology model system allows high throughput screening of immune check point inhibitors alone and in combination with other anti-cancer drugs for making it efficient for a broad range of tumor diseases.

In Booth Posters

InSphero In-Booth Posters

March 29 – April 3, during exhibit hours, Exhibition Hall Booth 3963

  • Akura™ Flow Scalable Organ-on-a-Chip Platform
  • Akura™ 96 and 384 Plate Technologies
  • 3D InSight™ Oncology Platform
  • 3D InSight™ PDX Microtissues